Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. develops clinical-stage therapies for unmet medical needs, with news centered on pipeline progress, regulatory authorizations, intellectual property and financing activity. Company updates frequently cover HT-001, a topical therapeutic for EGFR inhibitor-associated skin toxicities in cancer patients, as well as HT-VA/GDNF metabolic research tied to obesity, MAFLD and related liver-fat pathways.
Other HOTH news themes include patent protection for mast-cell targeting splice-switching oligonucleotide technology, use of the OpenClaw AI-enabled platform for drug-discovery analysis, and capital formation through registered direct offerings and warrant issuances. The company’s public updates generally reflect early-stage pharmaceutical research moving from preclinical work into clinical development.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the granting of U.S. Patent No. 10,793,525 for novel 13-Cis-RAMBA retinamides aimed at targeting cancer-associated signaling pathways. This first-of-its-kind patent expires on October 5, 2036. The compounds are designed to disrupt the MNK1/2-driven signaling pathway linked to various cancers, including breast and prostate cancer. Hoth's CEO, Robb Knie, emphasized the patent's contribution to their diverse intellectual property portfolio, which supports continued development in oncology and dermatology therapeutics.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) reported progress on its HT-003 acne treatment, demonstrating the ability to inhibit toll-like receptor 2 (TLR2) gene expression in human keratinocytes, crucial for acne pathophysiology. The research led by Dr. Jonathan Zippin showed no toxicity at doses up to 50 µM. Future testing will focus on determining the minimal effective dose and studying HT-003's broader applications for inflammatory diseases. Hoth aims to enhance life quality for patients with dermatological disorders through innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered a Sponsored Research Agreement with George Washington University to develop a rapid diagnostic device for SARS-CoV-2. This mobile testing solution aims to provide immediate COVID-19 test results using a plasmonic system, allowing patients to detect the virus anywhere. The device has potential for significant public health impact by streamlining testing processes. Initial discussions with the FDA regarding emergency use authorization are planned for early 2021.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Dr. Stefanie Johns will join as Chief Scientific Officer and appears on One America News Network on September 1, 2020, at 3:00 PM ET. Dr. Johns will discuss Hoth's recent licensing of a real-time, breath-based COVID-19 mobile testing device. Hoth is a clinical-stage biopharmaceutical company focusing on therapies for dermatological disorders and has entered agreements for developing two vaccine prospects related to COVID-19.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced the appointment of Stefanie Johns, Ph.D., as Chief Scientific Officer, effective September 2020. Dr. Johns has over 8 years of experience in the biopharmaceutical and medical device sectors, having previously worked as Director of Regulatory Affairs at Enable Injections, Inc. She is expected to enhance Hoth's pipeline, particularly the pipeline slated for clinical trials in Q4 2020.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its CEO, Robb Knie, will present at three investor conferences in September 2020. These events include the LD 500 Virtual Investor Conference on September 3 at 12:20 p.m. ET, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16 at 1:30 p.m. ET, and the Sidoti & Company 2020 Fall Virtual Investor Conference on September 23 at 2:30 p.m. ET. Management will also be available for one-on-one meetings with investors during these events.
Hoth Therapeutics (NASDAQ: HOTH) updated shareholders on its COVID-19 initiatives and dermatological therapies. The company is advancing its pipeline, including the BioLexa platform for atopic dermatitis, and submitted for ethics board approval in Australia for clinical trials. Hoth licensed VNLG-152 for dermatological diseases and partnered with George Washington University to explore WEG-232 for Erlotinib side effects. Notably, Hoth is developing a breath-based COVID-19 testing device and a self-assembling vaccine platform, with preclinical testing underway.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has submitted an ethics approval request to the Bellberry Human Research Ethics Committee in Australia for its upcoming clinical study of BioLexa, aimed at treating atopic dermatitis. The study will be a randomized, double-blind, vehicle-controlled trial assessing the safety, tolerability, pharmacokinetics, and efficacy of BioLexa in patients with mild to moderate atopic dermatitis. This marks a significant step in Hoth's clinical development program, as stated by CEO Robb Knie, highlighting the company's commitment to advancing innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its participation in LD Micro's Zooming with LD on August 11, 2020, at 8 AM PDT. CEO Robb Knie will present an overview of the company's operations and recent advancements, particularly the development of a breath-based COVID-19 mobile testing device. This virtual presentation marks an important opportunity for Hoth to showcase its innovations in biopharmaceuticals, especially in treating dermatological disorders and COVID-19 vaccine development. For access, use the password HOTHwithLD.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) will present at LD Micro's Zooming with LD on August 11, 2020. CEO Robb Knie will discuss the company's recent developments, including a license for a breath-based COVID-19 testing device. The presentation is set for 8 AM PDT and will take place virtually via Zoom, accessible with the password HOTHwithLD. Hoth Therapeutics is focused on developing innovative therapies for dermatological conditions and is also advancing two COVID-19 vaccine prospects.